ストックスクリーナーアプリを入手
0.7243
65.37%
0.2863
アフターアワーズ：
.66
-0.0643
-8.88%
前日終値:
$0.438
開ける：
$0.42
24時間の取引高:
65.64M
Relative Volume:
8.28
時価総額：
$70.74M
収益：
$27.47M
当期純損益:
$-26.60M
株価収益率:
-2.3111
EPS:
-0.3134
ネットキャッシュフロー:
$-21.86M
1週間 パフォーマンス:
+164.54%
1か月 パフォーマンス:
+155.30%
6か月 パフォーマンス:
-7.73%
1年 パフォーマンス:
-9.46%
1日の値動き範囲:
$0.42
$0.74
1週間の範囲:
$0.21
$0.74
52週間の値動き範囲:
$0.1657
$1.03
Cue Biopharma Inc Stock (CUE) Company Profile
Compare CUE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7243 | 42.78M | 27.47M | -26.60M | -21.86M | -0.3134 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-13 | 開始されました | Jefferies | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2022-11-21 | 開始されました | Piper Sandler | Overweight |
| 2022-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-03 | 開始されました | Craig Hallum | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-04-09 | 開始されました | Stifel | Buy |
| 2020-01-28 | 開始されました | BTIG Research | Buy |
| 2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Cue Biopharma to present preclinical data on CUE-401 at AAI meeting - Investing.com
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - The Manila Times
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
Cue Biopharma Inc stock (US22966J1060): Does its Immuno-STAT platform deliver the T-cell breakthroug - AD HOC NEWS
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
Cue Biopharma, Inc. Files Form 8-K with SEC Detailing Company and Stock Information (April 13, 2026) 30 - Minichart
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Shareholders Approve Reverse Stock Split Flexibility - TipRanks
[8-K] Cue Biopharma, Inc. Reports Material Event - Stock Titan
Cue Biopharma receives $7.5M milestone payment from Boehringer Ingelheim - MSN
Cue Biopharma : CUE - 24/7 Wall St.
Exit Recap: Can Cue Biopharma Inc be recession proofCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cue Biopharma (CUE) SVP and counsel receives 200,000 stock options - Stock Titan
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Executive at Cue Biopharma (CUE) granted 100K stock options - Stock Titan
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory DiseasesSlideshow (NASDAQ:CUE) 2026-04-09 - Seeking Alpha
Milestone under Cue and Boehringer Ingelheim collaboration - BioWorld News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - Bitget
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim By Investing.com - Investing.com Australia
Boehringer pays Cue Biopharma $7.5M to progress lead autoimmune asset - The Pharma Letter
Cue Biopharma (CUE) Achieves Preclinical Milestone with Boehring - GuruFocus
Cue Biopharma to receive $7.5 million preclinical milestone payment from Boehringer Ingelheim collaboration and license agreement - marketscreener.com
Cue Biopharma To Receive $7.5 Million Preclinical Milestone Payment From Boehringer Ingelheim Collaboration And License Agreement - TradingView
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim - Investing.com
A drug partner just triggered a $7.5M payout for Cue Biopharma - Stock Titan
Cue Biopharma R&D Day: CUE-401 IND Filing Targeted for Q2, Phase 1 Data Expected Late 2026 - Defense World
CUE: CUE-401 is set for phase I trials, backed by strong preclinical data and robust partnership funding - TradingView — Track All Markets
Cue Biopharma, Inc. Files Form 8-K SEC Report for April 2026 – Company Details, Stock Information, and Executive Signature - Minichart
Cue Biopharma says preclinical milestone triggers $7.5 mln payment under Boehringer deal - marketscreener.com
Cue Biopharma Says Preclinical Milestone Triggers $7.5 Mln Payment Under Boehringer Deal - TradingView — Track All Markets
Cue Biopharma Reaches Key Preclinical Milestone With Boehringer - TipRanks
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim - Investing.com
Cue Biopharma to receive $7.5M preclinical milestone payment from Boehringer Ingelheim - TradingView — Track All Markets
$7.5M Boehringer milestone advances Cue Biopharma (CUE) B cell program - Stock Titan
CUE Should I Buy - Intellectia AI
CUE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
CUE News & Events - Intellectia AI
CUE.O Forecast — Price Prediction for 2026. Should I Buy CUE.O? - Intellectia AI
CUE.O Technical Analysis & Stock Price Forecast - Intellectia AI
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
IPO Launch: Is Cue Biopharma Inc benefiting from interest rate changesWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cue Biopharma Appoints Lucinda Warren Interim CEO - citybiz
Cue Biopharma names Lucinda Warren interim CEO By Investing.com - Investing.com Australia
Cue Biopharma CEO Resignation Leads to 8% Stock Drop - Intellectia AI
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):